February 3, 2023
You are here:  Home  >  Banking & Finance  >  Tri-County Public Companies  >  Earnings  >  Current Article

Atara Biotherapeutics net losses worse than expected by analysts


Second quarter net losses for Atara Biotherapeutics outpaced analyst expectations, nearly doubling from the same period in 2017 to $50.9 million. Research and development costs rose 82.5 percent to $33.4 million, including new clinical trials, increased headcount and its recent expansion into a new R&D headquarters in Thousand Oaks. The company received positive results from…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.